IMV Inc. (IMVIF) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Dartmouth, NS, 加拿大. 现任CEO为 Andrew Hall.
IMVIF 拥有 IPO日期为 2013-04-08, 63 名全职员工, 在 Other OTC, 市值为 $117.00.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
